0001562180-20-004454.txt : 20200612
0001562180-20-004454.hdr.sgml : 20200612
20200612171937
ACCESSION NUMBER: 0001562180-20-004454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200610
FILED AS OF DATE: 20200612
DATE AS OF CHANGE: 20200612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tilton John
CENTRAL INDEX KEY: 0001704251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 20961136
MAIL ADDRESS:
STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
STREET 2: 234 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-06-10
false
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001704251
Tilton John
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN
CT
06510
false
true
false
false
Chief Commercial Officer
Common Shares
2020-06-10
4
M
false
52000.00
9.29
A
52770.00
D
Common Shares
2020-06-10
4
S
false
21364.00
66.7027
D
31406.00
D
Common Shares
2020-06-10
4
S
false
22838.00
67.5293
D
8568.00
D
Common Shares
2020-06-10
4
S
false
5331.00
68.5665
D
3237.00
D
Common Shares
2020-06-10
4
S
false
2467.00
69.3968
D
770.00
D
Employee Stock Option (right to buy)
9.29
2020-06-10
4
M
false
52000.00
0.00
D
2027-01-30
Common Shares
52000.00
37292.00
D
These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.05 - $67.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.05 - $68.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 - $68.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.05 - $69.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The shares underlying this option vested as to 50% of the shares on January 31, 2017, with the remainder vesting in 2 equal installments on the first and second anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.
/s/ Jim Engelhart, Attorney-in-Fact
2020-06-12